FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2997548008> ?p ?o ?g. }

• W2997548008 endingPage "4" @default.
• W2997548008 startingPage "4" @default.
• W2997548008 abstract "<ns7:p><ns7:bold>Background: </ns7:bold>Anthracycline- and taxane-based regimens form the mainstay of chemotherapy treatment in metastatic breast cancer. In patients who develop resistance to these agents, management options are limited and there is no standard of care. Thus, investigation into other chemotherapeutic agents is warranted.</ns7:p><ns7:p> <ns7:bold>Methods: </ns7:bold>In this non-randomised prospective trial, patients with human epidermal growth factor 2 (HER-2)-negative locally advanced or metastatic breast cancer that were anthracycline- and taxane-resistant were treated with carboplatin at a dose equivalent to an area under the concentration–time curve of 4.5 mg/ml.min on day 1 and gemcitabine 1500 mg/m<ns7:sup>2 </ns7:sup>on day 2 of every 2-week cycle. The primary end point was overall response rate.</ns7:p><ns7:p> <ns7:bold>Results: </ns7:bold>A total of five patients were enrolled prior to early termination due to difficulty in recruitment. The principal reason for recruitment difficulty was mandating anthracycline and taxane pre-treatment and HER-2 negativity. One patient had a complete response, one had a partial response, one had stable disease and two had progressive disease. Grade 4 neutropenia occurred in two patients.</ns7:p><ns7:p> <ns7:bold>Conclusions: </ns7:bold>In this patient population, inclusion criteria that are too stringent may result in difficulties reaching recruitment targets. Carboplatin in combination with gemcitabine appears to be a safe option for treatment of patients with locally advanced or metastatic breast cancer. Due to the small sample size, it is not possible to draw firm conclusions regarding efficacy from this trial.</ns7:p><ns7:p> <ns7:bold>Registration: </ns7:bold>EU Clinical Trials Register ID <ns7:ext-link xmlns:ns8=http://www.w3.org/1999/xlink ext-link-type=uri ns8:href=https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-005164-83/GB>2005-005164-83</ns7:ext-link>, registered on 10 April 2006.</ns7:p>" @default.
• W2997548008 created "2020-01-10" @default.
• W2997548008 creator A5000041911 @default.
• W2997548008 creator A5017543493 @default.
• W2997548008 creator A5027160662 @default.
• W2997548008 creator A5028884075 @default.
• W2997548008 creator A5060493962 @default.
• W2997548008 creator A5062000884 @default.
• W2997548008 creator A5069477380 @default.
• W2997548008 creator A5078099654 @default.
• W2997548008 creator A5086199896 @default.
• W2997548008 creator A5089085514 @default.
• W2997548008 date "2020-01-06" @default.
• W2997548008 modified "2023-10-17" @default.
• W2997548008 title "A phase 2 open-label study of carboplatin in combination with gemcitabine as a dose-dense schedule in patients with locally advanced or metastatic breast cancer that are resistant to anthracyclines and taxanes" @default.
• W2997548008 cites W1757407923 @default.
• W2997548008 cites W1828283074 @default.
• W2997548008 cites W1964414545 @default.
• W2997548008 cites W1966598565 @default.
• W2997548008 cites W1974767195 @default.
• W2997548008 cites W1977628815 @default.
• W2997548008 cites W2002970629 @default.
• W2997548008 cites W2004869577 @default.
• W2997548008 cites W2013246214 @default.
• W2997548008 cites W2025135843 @default.
• W2997548008 cites W2029409133 @default.
• W2997548008 cites W2038203496 @default.
• W2997548008 cites W2040512792 @default.
• W2997548008 cites W2058745329 @default.
• W2997548008 cites W2084095038 @default.
• W2997548008 cites W2089349521 @default.
• W2997548008 cites W2093051851 @default.
• W2997548008 cites W2116996913 @default.
• W2997548008 cites W2123732467 @default.
• W2997548008 cites W2152044355 @default.
• W2997548008 cites W2267376886 @default.
• W2997548008 cites W2289033501 @default.
• W2997548008 doi "https://doi.org/10.12688/f1000research.21804.1" @default.
• W2997548008 hasPublicationYear "2020" @default.
• W2997548008 type Work @default.
• W2997548008 sameAs 2997548008 @default.
• W2997548008 citedByCount "0" @default.
• W2997548008 crossrefType "journal-article" @default.
• W2997548008 hasAuthorship W2997548008A5000041911 @default.
• W2997548008 hasAuthorship W2997548008A5017543493 @default.
• W2997548008 hasAuthorship W2997548008A5027160662 @default.
• W2997548008 hasAuthorship W2997548008A5028884075 @default.
• W2997548008 hasAuthorship W2997548008A5060493962 @default.
• W2997548008 hasAuthorship W2997548008A5062000884 @default.
• W2997548008 hasAuthorship W2997548008A5069477380 @default.
• W2997548008 hasAuthorship W2997548008A5078099654 @default.
• W2997548008 hasAuthorship W2997548008A5086199896 @default.
• W2997548008 hasAuthorship W2997548008A5089085514 @default.
• W2997548008 hasBestOaLocation W29975480081 @default.
• W2997548008 hasConcept C121608353 @default.
• W2997548008 hasConcept C126322002 @default.
• W2997548008 hasConcept C143998085 @default.
• W2997548008 hasConcept C203092338 @default.
• W2997548008 hasConcept C2775930923 @default.
• W2997548008 hasConcept C2776694085 @default.
• W2997548008 hasConcept C2776802502 @default.
• W2997548008 hasConcept C2777511904 @default.
• W2997548008 hasConcept C2778239845 @default.
• W2997548008 hasConcept C2780258809 @default.
• W2997548008 hasConcept C2781451048 @default.
• W2997548008 hasConcept C530470458 @default.
• W2997548008 hasConcept C535046627 @default.
• W2997548008 hasConcept C71924100 @default.
• W2997548008 hasConceptScore W2997548008C121608353 @default.
• W2997548008 hasConceptScore W2997548008C126322002 @default.
• W2997548008 hasConceptScore W2997548008C143998085 @default.
• W2997548008 hasConceptScore W2997548008C203092338 @default.
• W2997548008 hasConceptScore W2997548008C2775930923 @default.
• W2997548008 hasConceptScore W2997548008C2776694085 @default.
• W2997548008 hasConceptScore W2997548008C2776802502 @default.
• W2997548008 hasConceptScore W2997548008C2777511904 @default.
• W2997548008 hasConceptScore W2997548008C2778239845 @default.
• W2997548008 hasConceptScore W2997548008C2780258809 @default.
• W2997548008 hasConceptScore W2997548008C2781451048 @default.
• W2997548008 hasConceptScore W2997548008C530470458 @default.
• W2997548008 hasConceptScore W2997548008C535046627 @default.
• W2997548008 hasConceptScore W2997548008C71924100 @default.
• W2997548008 hasFunder F4320307758 @default.
• W2997548008 hasLocation W29975480081 @default.
• W2997548008 hasLocation W29975480082 @default.
• W2997548008 hasOpenAccess W2997548008 @default.
• W2997548008 hasPrimaryLocation W29975480081 @default.
• W2997548008 hasRelatedWork W1988796172 @default.
• W2997548008 hasRelatedWork W2053822401 @default.
• W2997548008 hasRelatedWork W2089349521 @default.
• W2997548008 hasRelatedWork W2158628995 @default.
• W2997548008 hasRelatedWork W2356028434 @default.
• W2997548008 hasRelatedWork W2358893801 @default.
• W2997548008 hasRelatedWork W2388022328 @default.
• W2997548008 hasRelatedWork W2393254282 @default.
• W2997548008 hasRelatedWork W2415253097 @default.
• W2997548008 hasRelatedWork W2436215013 @default.
• W2997548008 hasVolume "9" @default.

• next